The American College of Cardiology (ACC) and American Heart Association (AHA) released a guideline for the therapy of blood cholesterol intended to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) in an adult.
Once a person is recognized as being at risk, then a statin and its dose are selected to match the required intensity of therapy.
|
Intensity of Therapy |
Goal |
|
high |
reduce LDL-C by >= 50% from baseline |
|
moderate |
reduce LDL-C by 30-50% from baseline |
|
low |
reduce LDL-C by < 30% from baseline |
|
Statin |
High Intensity |
Moderate Intensity |
Low Intensity |
|
atorvastatin |
80 (40) mg |
10 (20) mg |
NA |
|
fluvastatin |
NA |
40 mg bid (XL 80 mg) |
20-40 mg |
|
lovastatin |
NA |
40 mg |
20 mg |
|
pitavastatin |
NA |
2-4 mg |
1 mg |
|
pravastatin |
NA |
40 (80) mg |
10-20 mg |
|
rosuvastatin |
20 (40) mg |
10 (5) mg |
NA |
|
simvastatin |
NA |
20-40 mg |
10 mg |
Purpose: To evaluate a patient for statin therapy based on the 2013 ACC/AHA recommendations.
Specialty: Endocrinology, Cardiology, Clinical Laboratory
Objective: risk factors, options
ICD-10: I25.0, I25.1, I70,
